TITLE:
The Administration of Ocoxin Increases the Quality of Life of Patients with Advanced Epithelial or Metastatic Ovarian Cancer Undergoing Neoadjuvant Chemotherapy
AUTHORS:
Karen López Miguel, Daniel Ricardo Martínez Ávila, Lliset Álvarez Pérez, Gisselle Martínez Rabasa, Alejandro Linchenat Lambert, Roberto Esperón Noa, Lisandra Heredia Manzano, Margarita De Quesada Amigó, Rafael I. Reyes Velázquez, Danay Corrales Otero, Ramon Ropero Toirac, Idelmis Curbelo Heredia, Mircea Betancourt Cabeza, Tania A. Agrelo Ramos, Rosa María Muñoz Reyes, Juan Jesús Lence Anta, Rosalía Fuentes Sosa, Karelia Silvera Candó, Kirenia Silva Rodríguez, Zaida Lastre Sosa, Mayte Robaina García, Eduardo Sanz, David Marquez
KEYWORDS:
Chemotherapy, Radiotherapy, Ovarian Cancer, Oncology, Quality of Life, Ad-juvant Therapy, Supportive Care
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.13 No.9,
September
13,
2022
ABSTRACT: Background: 70% of ovarian cancer cases
are diagnosed at an advanced stage (III or IV) of the disease and, in turn,
with a high prevalence of peritoneal carcinosis and ascites, which leads to
progressive malnutrition in patients, with the consequent deterioration of their
general condition. There is a very important relationship between nutritional
status, quality of life, survival, and the
ability to tolerate multidisciplinary treatment of peritoneal carcinosis. Methods: A phase II, open-label, single-center, non-randomised clinical
trial was conducted that included 36 patients with advanced disease who were
administered the nutritional supplement Ocoxin, 30 ml twice a day, beginning
one week before chemotherapy (CT) based on carboplatin/paclitaxel, of which
they receive three cycles with neoadjuvant intent. Ocoxin treatment was
continued during chemotherapy and for three weeks after completion of the last
cycle, as well as during any periods for which this treatment was discontinued due to toxicity. The effect of Ocoxin on the
quality of life was assessed through the QLQ C30 and QLQ OV28
questionnaires from the start of treatment until the end of the follow-up
period. In addition, the Karnofsky Index and nutritional parameters were
assessed. Results: There were no significant differences between adverse events versus baseline values,
except in leukocytes, lymphocytes, neutrophils, ALT, and AST. There was
no deterioration of the QoL scales, except for those related to the effects of
chemotherapy and alopecia. Conclusions: Ocoxin as an adjuvant to
chemotherapy appears to improve better tolerance to chemotherapy, showed a good
safety profile, and improved quality of life.
For further information on Ocoxin neoadjuvant therapy benefits, a phase
III clinical trial will be needed.